An observational study in Generalized Anxiety Disorder and Oxygenation Sensitive CMR, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is one of 5 that started in 2022, is one of 5 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 44th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:
Claudio N Soares · Sites in Canada
Ages 18–60
Fraser Health · Sites in Canada
Ages 19+
Queen's University · Sites in Canada
Ages 18–65
Universite du Quebec en Outaouais · Sites in Canada
Ages 14–18 · Healthy volunteers
Dr. Rafael Freire · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 270 across 62 observational studies indexed under Generalized Anxiety Disorder.
Median enrollment 63 across the 45 interventional studies, 380 across the 5 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 1 study filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Generalized Anxiety Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
| NCT05574140McGill University Health Centre/Research Institute of the McGill University Health CentreBreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to view variations in MRI measurements of the heart and the brain in people with anxiety versus healthy volunteers. The MRI measurements used will be Oxygenation-Sensitive Cardiac MRI (OS-CMR), a recent type of MRI which is safe, fast, and non-invasive.
The investigators will prospectively analyze OS-CMR data from patients with a generalized anxiety disorder from one site. The investigators will observe how an anxiety disorder affects the OS-CMR data. In a follow-up MRI scan, the investigators will look at the OS-CMR of a subgroup who have anxiety disorder and are also undertaking cognitive behavioural therapy to asses how and if this therapy affects the OS-CMR data.
The study will recruit patient participants who are identified as having Generalized Anxiety Disorder (GAD), as well as age-similar healthy volunteer participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient population:
Age 18-55,
Healthy Volunteers:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with Generalized Anxiety Disorder
Diagnostic Test: Cardiac MRI
Participants with no pre-existing conditions and who are on no medications.
Diagnostic Test: Cardiac MRI
The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
Also known as: Breathing Maneuvers
Change in Signal Intensity
Change in signal intensity between the baseline signal intensity and the signal intensity at 30 seconds of breath hold
Time frame: Baseline
Started Jul 2022 (actual). Primary completion is estimated for May 2027, 57 months after the start.
Of 24 observational studies under Generalized Anxiety Disorder, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's planned 57 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Mar 2025 → May 2027 and completion Sep 2025 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
McGill University Health Centre/Research Institute of the McGill University Health Centre →